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Abstract 
Background: Understanding the occurrence of yellow fever epidemics is critical for targeted interventions and 
control efforts to reduce the burden of disease. We assessed data on the yellow fever incidence and mortality rates in 
Africa.
Methods: We searched the Cochrane Library, SCOPUS, MEDLINE, CINAHL, PubMed, Embase, Africa-wide and Web 
of science databases from 1 January 1975 to 30th October 2020. Two authors extracted data from included studies 
independently and conducted a meta-analysis.
Results: Of 840 studies identified, 12 studies were deemed eligible for inclusion. The incidence of yellow fever per 
100,000 population ranged from < 1 case in Nigeria, < 3 cases in Uganda, 13 cases in Democratic Republic of the 
Congo, 27 cases in Kenya, 40 cases in Ethiopia, 46 cases in Gambia, 1267 cases in Senegal, and 10,350 cases in Ghana. 
Case fatality rate associated with yellow fever outbreaks ranged from 10% in Ghana to 86% in Nigeria. The mortality 
rate ranged from 0.1/100,000 in Nigeria to 2200/100,000 in Ghana.
Conclusion: The yellow fever incidence rate is quite constant; in contrast, the fatality rates vary widely across African 
countries over the study period. Standardized demographic health surveys and surveillance as well as accurate diag-
nostic measures are essential for early recognition, treatment and control.
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Background
Yellow fever is an acute systemic illness caused by flavi-
virus transmitted by infected mosquitoes belonging to 
the Aedes and Haemogogus species [1]. Most of the yel-
low fever cases identified in Africa are seen in the unvac-
cinated population who live in the yellow fever belt. 
In severe cases, this viral infection causes high fever, 
bleeding into the skin and death of cells in the liver and 
kidney [2]. Currently, there is no treatment, cure or 
drugs for yellow fever but the disease can be prevented 
through vaccination. A yellow fever vaccine is available 
and recommended to laboratory workers, children over 
9  months and people who are traveling to or living in 
yellow fever high-risk areas of Africa [3]. A diagnosis of 
yellow fever is difficult to make as the definition for sus-
pected cases is based on similar signs and symptoms to 
other diseases like malaria, typhoid, dengue fever and 
other haemorrhagic fevers. Laboratory diagnosis exists, 
but the availability and lack of diagnostic capacity are 
major challenges in African countries. Consequently, it 
is a major public health problem often underreported in 
Africa.
Yellow fever has three modes of transmission cycles 
(Fig. 1). The first is sylvatic or jungle yellow fever. It hap-
pens when monkeys living in the tropical rainforest are 
infected through mosquitoes bites; and when humans 
visit or work in the jungle, the virus is transmitted from 
monkeys to humans by mosquitoes [4]. Other mosquitos 
that do not carry the virus become infected when they 
Open Access
*Correspondence:  pnyasulu@sun.ac.za
1 Division of Epidemiology & Biostatistics, Faculty of Medicine & Health 
Sciences, Stellenbosch University, Cape Town, South Africa
Full list of author information is available at the end of the article
Page 2 of 11Nwaiwu et al. BMC Infect Dis         (2021) 21:1089 
feed on the blood of the bitten monkeys, and the cycle 
continues [4]. In Africa, yellow fever is transmitted by 
five sylvatic vectors among which four are sylvatic (Ae. 
africanus, Ae. furcifer, Ae. taylori and Ae. luteocephalus) 
and one is intermediate savannah (Ae. aegypti) [5].
The second is the intermediate yellow fever (savannah) 
cycle, which includes the transmission of the virus from 
mosquitoes to humans living or working in the jungle 
border areas [4]. In this cycle, the virus can be transmit-
ted from monkey to human or from human to human 
through mosquitoes [4]. While the third is urban yel-
low fever, which includes the transmission of the virus 
between humans and urban mosquitoes, mainly Ae. 
aegypti [6]. The virus spreads in the urban environment 
through humans who were infected through mosquito 
bites in the forest or savannah. Outbreaks are typically 
triggered by sylvatic and intermediate forms where the 
virus is transmitted when humans come into close con-
tact with monkeys [6].
Yellow fever has a high case fatality rate, and there is 
no known cure for this disease [6]. Good in-hospital 
supportive treatment improves survival rate. In Africa 
and South America, 200,000 cases of yellow fever are 
recorded every year of which 90% occur in Africa, caus-
ing approximately 30,000 deaths [7]. It is estimated that 
as many as 610  million people in 32 African countries, 
including more than 219  million dwelling in urban set-
tings remain at high risk of contracting yellow fever [8].
The World Health Organization (WHO) has reported 
few cases of yellow fever from 1980, until 2016, when 
an upsurge in cases, to as high as 1040 at highly 
irregular intervals were recorded compared to cases 
between 1986 and 1995 [9, 10]. However, it is uncertain 
whether the recent increase in number of cases is due 
to increased surveillance or increased disease activity 
in these countries. Understanding yellow fever epide-
miology as determined by its evolution is important to 
develop preventative measures such as immunization 
policies to mitigate yellow fever infection. Yellow fever 
cases are frequently reported in West Africa than any-
where else in the world, followed by East Africa [11]. 
Major epidemics have occurred in West Africa posing 
global threats. An historical outbreak first of its’ kind 
was recorded in Kenya, East Africa, in 1992–1993 [11]. 
It was reported that two cases of yellow fever were 
imported to Europe from West Africa in recent years 
which had fatal outcomes, suggesting intercontinental 
transmission [11].
Due to lack of reporting of yellow fever cases in Africa, 
the overall burden of the disease may potentially be 
underestimated. The WHO estimated the burden of 
and associated mortality of yellow fever in Africa to be 
between 84,000–170,000 severe cases and 29,000–60,000 
deaths occurred in 2013 [12, 13]. While some estimates 
of the burden of yellow fever exists in Africa, we could 
not find a published systematic review and meta-analysis 
on yellow fever for the entire Africa continent. Thus this 
review was aimed to quantify and summarize the over-
all burden of and fatality associated with yellow fever in 
Africa.
Fig. 1 Transmission cycle of yellow fever virus
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Methods
Eligibility criteria
In this review, we considered outbreak reports, cross 
sectional studies and other observational studies (case 
series, case report, epidemiological surveys, surveillance 
studies etc.) including published and unpublished studies 
carried out in Africa that reported the incidence, mor-
tality and case fatality rate of yellow fever across all age 
groups. We included only patients who were considered 
to have suspected or confirmed cases of yellow fever. Sus-
pected cases were defined as cases that were character-
ized by acute onset of fever followed by jaundice within 
2 weeks of the onset of the first symptoms and confirmed 
cases as suspected cases that were laboratory-confirmed 
or epidemiologically linked to a laboratory-confirmed 
cases or outbreaks. Probable cases were defined as a sus-
pected case and one of the following: (i) epidemiologi-
cally link to a confirmed case or an outbreak; (ii) positive 
post-mortem liver histopathology.
We considered probable cases as being confirmed cases 
when they included any of the following: a probable case 
and one of the following: (i) detection of yellow fever-
specific IgM; (ii) detection of four-fold increase in yel-
low fever IgM and/or IgG antibody titres between acute 
and convalescent serum samples, (iii) detection of yellow 
fever virus-specific neutralizing antibodies.
All the different modes of transmission were consid-
ered and both hospital and field patients (population 
based) were included in this review.
Search method for identification of studies for inclusion
We exclusively searched the following databases: 
Cochrane library, MEDLINE, PUBMED, Embasse, SCO-
PUS, CINAHL (EBSCOhost), Africa-wide (EBSCOhost) 
and Web of science (SCI-EXPANDED) for studies pub-
lished from 1 January 1975 to 30 October 2020 includ-
ing unpublished studies. We selected the starting date of 
1975 because of the generally increasing availability and 
quality of published studies from that date. The combina-
tion of keywords was used to search for relevant studies 
from the electronic databases. We included the follow-
ing keywords: “outbreak”, “Burden of disease”, Incidence, 
Prevalence, Survey, Surveillance, Epidemic, Epidemiol-
ogy, “yellow fever”, “yellow jack”, “yellow fever vaccines”, 
vaccination”, seroprevalence, “haemorrhagic fever”, “Jun-
gle fever,” “cross sectional studies”. Boolean terms, AND/
OR were used during the keywords search to identify 
relevant studies. Regional grouping such as sub-Saharan 
Africa and West Africa were also used to look for stud-
ies indexed under regional names. Medical Subject 
Heading (MesH) terms were used in PubMed and Med-
line search (Additional file  1: Table  S1). In consultation 
with a medical librarian, peer-reviewed journal papers 
were searched systematically in SCOPUS, Africa-wide 
(EBSCOhost) and Web of science (SCI-EXPANDED) 
using variations of MeSH terms (Additional file  1: 
Table S1). Lastly, we also controlled vocabulary (subject 
headings) to search CINAHL, and Embase.
We identified three conferences related to yellow fever 
through a Google search: International Society for Infec-
tious Diseases (ISID), International Congress on Infec-
tious Diseases (ICID) and International Conference on 
Infectious Disease Dynamics (ICIDD). We searched for 
the following terms on the website of each of the three 
conferences identified: yellow fever, incidence, mortal-
ity, and Africa. We also consulted an expert librarian at 
Stellenbosch University, South Africa, to improve and 
sharpen the search strategy (Additional file 1: Table S1). 
We identified other eligible studies by searching the ref-
erence list of included studies.
Data extraction
Two review authors independently and in duplicate 
screened titles and abstracts and selected studies for 
inclusion in this review using the set eligibility criteria. 
The identified studies were retrieved for full texts and 
included in the review after re-screening. Screening and 
data extraction was done using Covidence manager. Any 
discrepancies were resolved by consensus or by a third 
reviewer. We independently and in duplicate extracted 
the data on the following: burden of disease, character-
istics of the participants, study setting, study design, 
date of study, study location. Risk of bias for each of the 
included studies was assessed using the validated quality 
appraisal tool developed by Hoy and colleagues (Addi-
tional file 1: Table S3) [14]. We assessed each domain as 
either low or high risk of bias and regarded studies which 
were unclear as high risk of bias. We scored the overall 
risk of bias according to the number of high risk of bias 
parameters per study: low (1–3), moderate (4–6) and 
high (7–9).
Data synthesis and management
All included studies focused on incidence, case fatality 
rate (CFR), and mortality. We calculated incidence by 
dividing the number of confirmed and suspected cases 
by the total population in that region and expressed it 
per 100,000 populations. We calculated 95% CI for the 
incidence using the standard formula for calculating the 
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where p = incidence (per 100,000), and n = sample size. 
We assumed normality of the incidence statistic and 
used the critical value of 1.96 while calculating the 95% 
confidence intervals. We calculated CFR by dividing the 
number of deaths from yellow fever over a defined period 
of time by the number of individuals diagnosed with yel-
low fever then multiplied by 100 to yield a proportion. 
Mortality rate was calculated by dividing the number of 
deaths by the total population and then multiplied by 
100,000.
We performed random-effects meta-analysis due 
to the variability in incidence estimates from differ-
ent countries. We assessed heterogeneity using both 
the Chi-square test (p < 0.10 considered significant) and 
the I-square test statistic (> 50% considered significant) 
[15]. We investigated sources of heterogeneity through 
subgroup analysis with respect to the country of study 
[14]. Heterogeneity was also explored by examining the 
potential differences in the characteristics of the popula-
tion such as the settings and other characteristics in the 
‘Characteristics of included studies’ table. We performed 
meta-analyses using STATA version 15 and displayed 
results using forest plots. However, due to significant het-
erogeneity in meta-analyses for incidence rate and CFR, 
we performed systematic reporting of the results per 
study per country. The meta-analysis for mortality rate 
was not possible due to insufficient data; the results for 
the mortality rate were reported narratively.
Results
Identification of studies for review
We identified 839 studies from electronic search of five 
databases. After removing duplicates, we screened the 
titles and abstracts of 493 published articles and excluded 
464 studies. We retrieved the full texts of the remaining 
29 studies and excluded 12 of these studies [1, 11, 16–25] 
because they either did not report on the yellow fever 
burden or were from non-African countries. From the 
17 studies that reported on yellow fever incidence, we 
excluded five more studies [18, 21–24] because they only 
reported on the evaluation of yellow fever vaccine with-
out reporting data on yellow fever burden. We included a 
final total of 12 studies (Fig. 2) [2, 26–36].
Characteristics of included studies
A summary table of characteristics of the included stud-
ies is presented in the appendices (Additional file  1: 
Table S2) We categorized studies based on year of assess-
ment, test methods implemented for confirming the 
diagnosis of yellow fever, and clinical case definition used. 
The number of studies published each year increased 
modestly from 1975 to 2018. Although studies originated 
from eight African countries, three studies were from 
Nigeria [27–29], two studies each from Senegal [31, 32] 
and Uganda [33, 34] and one study from each of the five 
countries, Kenya [30], Ethiopia [34], Ghana [26], Gambia 
[2] and Democratic Republic of Congo [35]. The major-
ity of studies ‘Seven’, were from West Africa [2, 26–32] 
‘Three’ studies from East Africa [30, 33, 36], ‘One’ from 
North Eastern Africa [34] and ‘One’ study from Central 
Africa [35]. All the three modes of yellow fever transmis-
sion considered in this review were reported by at least 
one study. Eight studies reported that the outbreak was 
due to sylvatic mode of transmission [2, 27, 30–34, 36], 
two studies reported that it was due to an urban mode 
of transmission [28, 35] and only one study reported the 
intermediate mode of transmission [36].
Ten of the studies [2, 26–29, 31–36] were reported from 
hospital and field-based surveillance studies while two 
studies [30, 33] were only from hospital-based surveil-
lance studies. Nine studies [2, 26–29, 31, 32, 36] included 
participants of all ages while four studies reported the 
disease in specific age groups such as from 10–70 years 
[30], 3  months–83  years [33], 3–64  years [36] and 
10–72 years [35], respectively. Nine of the included stud-
ies [2, 26, 29–34, 36] were conducted in rural areas, two 
[28, 35] in urban areas and one [34] in mixed rural/urban 
setting. The population reported in all the studies lived 
on subsistence farming, growing several crops and rear-
ing livestock. Most of the population under study prac-
ticed domestic water storage except for one study [34] 
that reported people practicing less livestock rearing and 
less domestic water storage while one study [35] did not 
report on any of the above. Rainy season and increased 
breeding sites were reported as risk factors for yellow 
fever epidemic as these can increase the mosquito popu-
lation. However, two studies [31, 36] did not attribute the 
outbreak to the rains rather reported that the study pop-
ulation were in contact with the forest for 2 years before 
returning from the Internally Displaced Persons camps. 
They found their homes dirty exposing them to multiple 
natural breeding sites for mosquitoes that could have led 
to the outbreak. All the included studies also reported 
that yellow fever was confirmed using viral serology by 
doing enzyme-linked immunosorbent assay (ELISA) to 
detect IgM antibodies to yellow fever virus, and to iso-
late the virus. Some of the studies for instance [28, 30], 
reported that histopathology on liver specimens were 
done. One study, reported that test for antibody neutrali-
zation was not done [36].
The duration of the outbreak lasted for 11  months 
in Ethiopia [34] followed by Gambia which lasted for 
8  months [2]. Outbreaks in Democratic Republic of 
Congo [35], Kenya [30], and Nigeria [27] lasted for 7, 6 
and 5  months, respectively. Another outbreak in Nige-
ria [30] lasted for 4  months. Two studies from Senegal 
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[31] lasted for 2  months and 1  month respectively [32] 
reported only 1  month. The other studies reported that 
the outbreak lasted for 3  months [28, 31, 32], while the 
study done in Ghana did not report the duration of the 
outbreak [26].
Assessment of risk of bias of included studies
We evaluated all the studies using the Hoy’s risk of bias 
tool [14]. Our summary assessment shows that ten 
studies were low risk of bias (83%) [2, 27–34, 36] and 2 
studies were moderate risk of bias (17%) (Additional 
file 1: Table S3).
Incidence of yellow fever
Meta-analysis of yellow fever incidence estimates 
from different studies and countries resulted in sig-
nificant heterogeneity  (I2 = 99.4%, p < 0.001) and there-
fore we map the results per study/region in Africa 
(Fig.  3). The two studies from Uganda reported very 
low incidence of less than 3 and 13 cases per 100,000 
population respectively, Kenya < 30 cases per 100,000, 
Fig. 2 PRISMA flow diagram showing results of studies on yellow fever in Africa
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Ethiopian 40 cases per 100,000, In Gambia < 50 cases 
per 100,000, Nigeria the incidence ranged from < 1 to 
over 80 cases per 100,000 population. The two studies 
in Senegal reported incidence rates of approximately 
1300 and 5900 cases per 100,000 population while 
Ghana reported the highest incidence which ranged 
between 320 to over 10,000 cases per 100,000 popula-
tion (Fig. 3).
Case fatality rate
Meta-analysis of CFR (in %) resulted in significant het-
erogeneity  (I2 = 95.6%, p < 0.001, Fig.  3) and therefore 
we report results narratively per study. The only study 
from Democratic Republic of Congo had the lowest CFR 
of just over 10%. The Ethiopian study reported a CFR of 
slightly over 30%, the two studies from Uganda reported 
CFRs of just over 30% each, while the one study from 
Fig. 3 Map showing incidence rates (cases per 100,000) of yellow fever in Africa
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Gambia reported a CFR of less than 30%. The CFRs in 
different regions of Ghana ranged from just over 16% 
in Volta Region to almost 40% in Brong Ahafo. The two 
Senegal studies reported high CFRs of 28% and 42%, 
while the Kenyan study reported a higher CFR of over 
60%. Lastly, the Nigerian studies reported varying CFRs 
from 11 to 85% (Fig. 4).
Mortality rate
We could not perform meta-analysis of mortality rate 
because the population sizes were not reported by most 
included studies. The results also differed widely such 
that a meta-analysis would likely result in high hetero-
geneity. We therefore reported the results narratively for 
each study. The two studies from Senegal had high mor-
tality rates ranging from over 500 to almost 1700 deaths 
per 100,000. The Ethiopian and Kenyan single studies had 
low mortality rates of 12 and 17 deaths per 100,000 pop-
ulation. In Uganda, the mortality rates were even lower, 
ranging from less than 1 to 4 deaths per 100,000 popula-
tion. In Gambia, it was 12 deaths per 100,000 population. 
In Ghana, the mortality rate ranged from just over 50 in 
Volta Region to over 2200 deaths per 100,000 population 
in the Eastern Region. The one study in DRC reported 
a low mortality rate of 1 death per 100,000 population. 
Lastly, the studies from Nigeria reported mortality rates 
ranging from 0.2 deaths per 100,000 population in Kwara 
State to more than 44 deaths per 100,000 population in 
South Eastern Nigeria.
Discussion
We carried out this systematic review with the objective 
of estimating the incidence and associated mortality of 
yellow fever in Africa. We found 12 studies from eight 
countries in Africa, suggesting that studies are scarce 
in yellow fever-endemic African countries. We found in 
studies in Nigeria [27–29], Uganda [33, 36], Senegal [31, 
32] Kenya [30], Ethiopia [34], Gambia [2], Ghana [26] 
and Democratic Republic of Congo [35]. ‘Eight’ studies 
were undertaken more than 20 years ago, and with only 
four recent studies. This shows there is scarcity of data, 
thereby making the true estimation of yellow fever inci-
dence difficult in Africa. However, data reported that 
yellow fever is a disease of the East and West African 
countries. We found that incidence of yellow fever varies 
in different countries. The incidence of yellow fever was 
highest in Senegal [31, 32] (1300–5900/100,000 followed 
by 320/100,000 in Ghana [26] and lowest in Uganda 
with a range of 3–13/100,000 [33, 36]. The reason for 
this increase could be due to an improved surveillance 
Fig. 4 Forest plot showing case fatality rates associated with yellow fever outbreaks in Africa
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reporting system. Case fatality rate was highest (60%) in 
Kenya and ranged from 11 to 85% in Nigeria while Dem-
ocratic Republic of Congo had the lowest case fatality 
rate of over 10% [28, 30, 35]. Finally, mortality rate was 
highest in Senegal [31, 32] 500–1700 deaths/100,000, 
Uganda [33, 36] had a low mortality rate of less than 1 
to 4 deaths/100,000 while Nigeria ranged from 0.2 to 44 
deaths/100,000 [27–29]. These results illustrated that the 
case fatality and mortality rates widely vary in the Afri-
can yellow fever belt. In comparison, a 25-year study in 
Africa estimated that 13% (95% CI 5–28%) of yellow fever 
infections presented as severe cases, with 46% (95% CI 
31–60%) of severe cases resulting in death [37]. These 
findings could also be as a result of better surveillance 
system and global awareness now compared to what we 
had previously. Some studies report that a combination 
of some factors like socioeconomic, demographic and 
ecological circumstances favoured the high incidence of 
yellow fever in Africa [36]. Other authors have indicated 
that Africa monkey are resistant to the yellow fever virus 
and if they become infected they usually do not die but 
rather become immune and humans become accidentally 
infected during their short forest activities [36]. Usu-
ally African population are at a higher risk of the disease 
because of very low immunity. This is due to low vacci-
nation coverage and also linked to their daily activities 
and occupation such as farming, deforestation, and cattle 
grazing, which bring them in close proximity to the forest 
where the vectors live.
From the studies that we included in this review, the 
outbreaks that occurred were due to sylvatic mode of 
transmission which involves the virus passed on between 
non-human primates (e.g., monkeys) and mosquito spe-
cies found in the forest canopy [26–29, 32–36]. Yellow 
fever is endemic in the sylvatic settings in Africa pre-
dominantly in East and West Africa. The sylvatic mode 
of transmission gives a more regular epidemic pattern as 
opposed to urban transmission which often gives a peri-
odic and more unpredictable outbreak. This information 
is ideal as it would help policy makers focus the strategies 
on how best to fight the regular clustering of yellow fever 
epidemic. Some of these strategies would include using 
an integrated mosquito management (IMM) [38] pro-
gram steps such as: (i) surveillance: this will help detect 
the different mosquito species in a given area and with 
this data, they are able to effectively time larvicide and 
adulticide activities; (ii) public education: this includes 
educating the general public on how to control mosquito 
breeding sites at their backyard; (iii) larval and adult mos-
quito control: inspecting sources of standing water look-
ing for mosquito larval so as to eliminate them before 
they become adults that can transmit the virus while the 
adult mosquitoes are treated using pesticides. We also 
noticed that yellow fever is endemic with the outbreaks 
occurring during rainy season. It is known that rainy 
season increases the breeding sites and the mosquito 
population which transmit the disease. Hence heavy 
and prolong rainfall result in high vector population 
due a favorable breeding environment for mosquitoes 
due to heavy rainfall during rainy season. This provides 
adequate ground to support continued circulation of the 
virus especially in the sylvatic cycle.
Previously, prevention of this disease was done through 
vector control which was very effective in reducing the 
occurrence of the disease. However, smaller outbreaks 
occur due to changes in the distribution of the disease 
and currently, vaccination strategies such as routine 
infant immunization, mass vaccination campaigns and 
vaccination of travelers going to yellow fever endemic 
regions are used to protect people against these out-
breaks. Yellow fever vaccine called 17D is known for pre-
venting the disease and just a single dose of the vaccine 
confers immunity and lifelong protection. The vaccine 
provides effective immunity within 10 days for 80–100% 
of people vaccinated, and within 30  days for more than 
99% of people vaccinated [39]. Most African countries 
where yellow fever is endemic have included yellow fever 
vaccine in the Expanded Programme on Immunization 
(EPI) schedule for new-born babies. Most of the yellow 
fever cases identified in Africa are seen in the unvacci-
nated population who live in the yellow fever belt. Some 
countries have sustained epidemics across multiple years 
like Ghana (1977–83), Guinea (2000–2005), Nigeria 
(1986–1994) and Congo (2011–2013) [37]. Looking at 
previous data on yellow fever over a period of 25  years 
in Africa, showed that yellow fever has been persistent in 
West and Central Africa [37]. In East Africa, yellow fever 
has mostly been in Kenya [37]. However, cases were also 
reported in Uganda and Ethiopia. The estimated annual 
provincial incidence in 32 African countries known to 
be endemic for yellow fever varied from 0.7 to 10% [37] 
which is low compared to the overall incidence rates 
found by this systematic review. A recent study reported 
that in 2018 there were approximately 109,000 (95% CI 
67,000–173,000) severe infections and 51,000 (95% CI 
31,000–82,000) deaths due attributed to yellow fever in 
Democratic Republic of Congo and Amazon region [40].
In December 2016, cases of yellow fever were detected 
in Luanda, the capital of Angola, which were previously 
in the category of low-risk areas for yellow fever. The 
disease spread rapidly from Luanda to other urban com-
munities in Angola and crossed into the neighbouring 
country of the Democratic Republic of Congo [16, 41]. 
This observation empathizes the fact that yellow fever 
is a neglected tropical disease which needs more public 
health strategies to contain it coupled with more studies 
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to be conducted in Africa to generate in-depth evidence 
for effective interventions.
Reviewing the vaccination coverage, WHO recom-
mends population vaccination coverage of 80% or more 
to prevent and control outbreaks. However, all of the 
regions included in this review has recorded low vacci-
nation coverage. A recent study showed the targeted ver-
sus the untargeted vaccination coverage of 54%/63% and 
24%/24% in Democratic Republic of the Congo (Central 
Kongo region), 61%/75% in Senegal (Kaffrine region), 
zero coverage in Ethiopia (South Omo zone), 67%/67% 
in Ghana (Volta, Brong Ahafo and Eastern Regions), 
zero coverage in Kenya (Kerio Valley), zero coverage in 
Uganda (Northern Uganda, Masaka, Kalungu, Kalangala 
and Rukungire regions) and 56%/65% in Nigeria (Cross 
river, Lagos, Oyo, Ogun, Ondo, Kwara and Imo state) 
[42]. As shown, all of the regions with a high incidence of 
yellow fever and case fatality rate in this review had less 
than 80% vaccination coverage, with some regions having 
0%.
The review has shown that yellow fever incidence 
seems to have been pretty constant throughout African 
countries over the inclusion period of the review. How-
ever, three of the studies included showed high inci-
dence rates [26, 31, 32]. In contrast, the fatality rates 
varied widely across African countries over the same 
period of the review. Since most of the studies were con-
ducted between 1984 and 1998, moderately high vaccina-
tion coverage rates across much of western and central 
Africa in the 1970s were the result of mass preventive 
campaigns in the 1940s to the 1960s [42, 43], which 
reduced the number of outbreaks [43]. Coverage declined 
between 1960 and 2000 in most areas due to limited vac-
cination activity, the birth of new unvaccinated cohorts, 
a steady decline in the proportion of older covered 
cohorts through mortality [43] and vaccine stock short-
ages, which have been frequently reported in the African 
region [44]. Past public health successes led to a lax in 
maintaining local yellow fever vaccination coverage lead-
ing to waning herd immunity and an eventual re-emer-
gence of large outbreaks in West Africa in the 2000s [42, 
45].
In fact, yellow fever may not easily be eliminated due 
to the presence of non-human wildlife reservoirs that 
sustain the sylvatic transmission cycle of the virus in 
non-urban settings, however the risk of a yellow fever 
outbreak can be eliminated if successful vector con-
trol, vaccination and surveillance of the disease are 
implemented and maintained [42]. The joint effort by 
the WHO, the United Nations International Children’s 
Emergency Fund (UNICEF), the Global Alliance for Vac-
cinations and Immunization (GAVI) and yellow fever 
virus (YFV) endemic countries created the Yellow Fever 
Initiative (YFI) in 2006 [46], which focused primarily on 
widespread yellow fever vaccination initiatives and the 
implementation of childhood immunization vaccine. In 
the context of an emergency preparedness effort, this 
initiative has created an opportunity for global stock of 
yellow fever vaccines [41, 47]. The 17D yellow fever vac-
cine is effective, safe, affordable, readily available, and 
can prevent the disease with just a single dose being suf-
ficient enough to confer sustained immunity and lifelong 
protection.
The review has limitations the main one being paucity 
of yellow fever incidence/prevalence data from different 
African countries. The incidence estimates from the dif-
ferent studies were significantly heterogeneous and there 
were not enough data from the studies to determine the 
sources of this heterogeneity, but could have been due to 
the different geographical nature in Africa, seasons, set-
tings (rural or urban), different populations, statistical 
methods and regional differences. Studies included in 
this review were fewer hence limiting the scope to gener-
ate more accurate estimates of the burden of yellow fever 
in African regions. Secondly most of the included stud-
ies were predominantly from East–West Africa, hence 
understanding the burden of yellow fever in other regions 
is restricted.
The risk of bias assessment showed that 83% of stud-
ies showed to have a low risk of bias, however included 
studies mighty not have been representative of a larger 
population. Furthermore, in most of the included studies, 
the number of confirmed and suspected cases were not 
clearly distinguished. As such this limits generalizability 
of the incidence and case fatality rate estimates to a larger 
African population.
Conclusion
This systematic review identified 12 observational stud-
ies assessing yellow fever incidence and fatality rates in 
Africa. Data shows that yellow fever incidence rate is 
quite constant across African countries with high inci-
dence rates reported in three studies of the 12 stud-
ies. The case fatality rates for yellow fever varied widely 
across Africa. However, the lack of reliable epidemio-
logical data on yellow fever in Africa compromises the 
public health priority that could give rise to yellow fever 
infection.
For that reason, it is essential to provide standardized 
demographic health surveys as a population surveillance 
strategy to track the burden of yellow fever as well as 
accurate diagnostic measures for early recognition and 
treatment of yellow fever. Knowing that yellow fever usu-
ally re-emerges in rural areas, rural facilities should be 
enforced in yellow fever prevention, management and 
reporting approach. Timely and accurate diagnosis of 
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yellow fever could avoid untoward case fatality rates and 
minimize under-reporting. Accurate yellow fever data is 
substantial for good public health policy and guide plan-
ning of vaccine volumes and delivery system. In addition, 
public health control strategy should focus on strength-
ening yellow fever prevention including incorporating 
yellow fever immunization schedules in African endemic 
countries and mandatory reporting of cases in primary, 
secondary and tertiary levels. Future research should 
focus on evaluating yellow fever immunogenicity in 
children.
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